Global Commercial Partnerships KalVista is actively pursuing and engaging distribution and commercialization collaborations through partners like Multicare Pharmaceuticals, signaling readiness for broader geographic market access and payer strategy support for its HAE therapies.

Pediatric Expansion Opportunities Recent pediatric developments and launches, including EKTERLY for use in children and positive pediatric data, create a strong opportunity for partners in pediatric formulation, regulatory strategy, and patient access programs.

Pipeline Collaboration Signals With a portfolio of small molecule protease inhibitors in development and potential strategic interest from acquirers, there are clear openings for licensing, co-development, or acquisition discussions around KalVista's assets.

Manufacturing and Supply Chain As a specialist in oral therapies for rare diseases, KalVista may seek contract manufacturing, formulation development, and supply chain partnerships to scale production and ensure robust commercial readiness.

Market Access and Payer Strategy The focus on global care and rare-disease therapy suggests demand for HEOR, pricing and reimbursement support, patient access programs, and payer engagement to optimize uptake of EKTERLY and future assets.